1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Refractory Hematologic Malignancy: new trials by email Literature Review of Refractory Hematologic Malignancy trials Research Report on Refractory Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. Tazemetostat, Tafasitamab, Lenalidomide - Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | Phase 1 / Phase 2 | Withdrawn | Epizyme, Inc. | 2021-12-22 | 2023-08-15 |
Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Neoplasms (1) · Neoplasms by Site (1)
Dexamethasone (1) · Lenalidomide (1) · acalabrutinib (1) · daratumumab (1) · pomalidomide (1) · tafasitamab (1) · tazemetostat (1)
Epizyme, Inc. (1)
United States (1)